top of page

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

PBLA-PR-definitive-agreement-2-22-22

.pdf

Download PDF • 209KB

Featured Posts

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Recent Posts

BullFrog AI Partners with the Sage Group to Explore JV Opportunities to Advance its Oncology Assets

The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist

AeroNeph Therapeutics Announces Search for Strategic Partners for Novel Drugs for Renal Disease

Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol

Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem

SalivaPod - Novel Saliva Sample Collection for a New Era of Diagnostics

Archive

Search By Tags

Follow Us

bottom of page